Study reveals new insights for personalized metastatic prostate cancer treatment.

Research from VHIO, published in Nature Medicine, offers new biological and clinical insights for personalized treatment of metastatic prostate cancer. The phase II ZZ-FIRST trial demonstrated that combining talazoparib and enzalutamide extended median radiographic progression-free survival to 45.3 months, significantly longer than enzalutamide alone (31.1 months). This study tracked tumor adaptation to treatment, revealing mechanisms of castration resistance and informing future therapeutic strategies.